Amenta F, Ferrante F, Sabbatini M, Ricci A
Sezione di Anatomia Umana, Università di Camerino, Italy.
Clin Exp Hypertens. 1994 May;16(3):359-71. doi: 10.3109/10641969409072222.
The effect of the Ca2+ channel blocker nicardipine on the circle of Willis and the different sized pial arteries was assessed in 20-week-old spontaneously hypertensive rats (SHR) using quantitative image analysis techniques. Normotensive Wistar Kyoto (WKY) rats were also used as a normotensive reference group. In SHR a significant increase of systolic blood pressure (SBP) is noticeable in comparison with WKY rats. The media-to-lumen ratio was increased in the circle of Willis arteries, large sized (diameter > than 150 microns), medium sized (diameter between 150 and 50 microns) and small sized (diameter < than 50 microns), pial artery branches. An increase in the thickness of the tunica media and a luminal narrowing was also seen in medium and small sized pial arteries of SHR in comparison with WKY rats. Treatment with an oral dose of 10 mg/Kg of nicardipine 3 h before the sacrifice significantly reduced SBP in SHR. The drug was without effect on circle of Willis and on large sized pial arteries. Moreover, treatment with nicardipine reduced the thickness of the tunica media, the media-to-lumen ratio and increased the luminal area in medium and small sized pial artery branches. These findings show that treatment of SHR with nicardipine significantly reduces SBP and causes a moderate vasodilatation of arteries regulating cerebrovascular resistance. This property may be useful in avoiding generalized or exaggerated cerebrovascular dilatation which could be accompanied by impaired brain perfusion in hypertension.
使用定量图像分析技术,在20周龄的自发性高血压大鼠(SHR)中评估了钙离子通道阻滞剂尼卡地平对 Willis 环和不同大小软脑膜动脉的影响。正常血压的Wistar Kyoto(WKY)大鼠也用作正常血压参考组。与WKY大鼠相比,SHR的收缩压(SBP)显著升高。Willis环动脉、大尺寸(直径大于150微米)、中尺寸(直径在150至50微米之间)和小尺寸(直径小于50微米)的软脑膜动脉分支的中膜与管腔比值增加。与WKY大鼠相比,SHR的中、小尺寸软脑膜动脉中膜厚度增加且管腔狭窄。在处死前3小时口服10mg/Kg尼卡地平可显著降低SHR的SBP。该药物对Willis环和大尺寸软脑膜动脉无作用。此外,尼卡地平治疗可减少中、小尺寸软脑膜动脉分支的中膜厚度、中膜与管腔比值,并增加管腔面积。这些发现表明,用尼卡地平治疗SHR可显著降低SBP,并引起调节脑血管阻力的动脉适度血管舒张。这一特性可能有助于避免可能伴随高血压时脑灌注受损的全身性或过度脑血管扩张。